Endosense www.endosense.com
Endosense于2003年在日内瓦成立，是一家医疗科技公司，致力于改善治疗心律失常的导管消融术的功效、安全性和易用性。公司在开发TactiCath*时率先在导管消融术中采用了触点压力测量，TactiCath是第一种压敏消融导管，允许医生在实施导管消融术时实时、客观地测量接触力。Endosense得到Edmond de Rothschild Investment Partners、Neomed、Gimv、VI Partners、Sectoral Asset Management、Ysios Capital Partners及Initiative Capital Romandie等投资公司的投资支持。

Endosense is a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. The company has pioneered the use of Contact Force in catheter ablation.

The company’s flagship product is the TactiCath Quartz®, the first force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. Already distributed in Europe, Australia and New Zealand, this force-sensing catheter has undergone extensive pre-clinical and clinical validation.

Endosense’s target patient population is sizeable, as the TactiCath Quartz® may be used to treat a range of cardiac rhythm disorders, including atrial fibrillation (AF).The current estimate of the prevalence of atrial fibrillation (AF) in the developed world is approximately 1.5–2% of the general population1 (six million patients in the US alone).

In the past, most AF patients have been treated with pharmaceutical drugs that do not address the underlying cause and have side effects, with invasive ablation surgery as the primary treatment alternative. Now, catheter ablation has become a minimally invasive and safe treatment option for atrial fibrillation.2